Literature DB >> 50349

Identification of the cell population involved in viral-specific cell-mediated cytotoxicity in man: evidence for T cell specificity.

M Rola-Pleszczynski, R C Hurtado, J N Woody, K W Sell, M M Vincent, S A Hensen, J A Bellanti.   

Abstract

The nature of the cell population involved in lymphocyte mediated cytotoxicity to baby-hamster-kidney (BHK-21) target cells persistently infected with rubella virus was investigated by a 51Cr-release microassay. After depletion of the T cell population with an antiserum to human0thymus-lymphoid tissue antigen (HTLA), the purified B cell population showed a decrease in E-rosette formation (9.0 +/- 2.2% compared to 69.6 +/- 9.1% before treatment) and an insignificant degree of cytotoxic activity against rubella-infected target cells (specific immune release of 51Cr was 0.9 +/- 2.6% compared to 24.2 +/- 3.8 before treatment). A purified T cell population, prepared by depletion of B cells with an anti-human immunoglobulin serum and complement, was found to show no alteration in E-rosette formation (85.2 +/- 6.2%) or cytotoxicity (30.3 +/- 4.4% SIR) but showed decreased EA- and EAC-rosette formation (2.7 +/- 1.5% and 10.5 +/- 3.2%, respectively, compared to 19.4 +/- 2.9% and 28.0 +/- 4.1% before treatment). A monocyte-depleted population prepared by removal of the plastic adherent mononuclear cells showed no significant alteration of rosette formation or cytotoxicity. These experiments suggest that the predominant lymphoid population responsible for direct cell-mediated cytotoxicity to virus infected target cells in the 51Cr-release microassay appears to be effected by a thymus-dependent lymphocyte population.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50349

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Effector cell involved in cell-mediated cytotoxicity to cells infected with herpes simplex virus type 1.

Authors:  I Heron; A Moller-Larsen; K Berg
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

2.  Immune effector cell activity in canines: failure to demonstrate genetic restriction in direct antiviral cytotoxicity.

Authors:  C K Ho; L A Babiuk; B T Rouse
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

3.  Cells that express viral antigens but lack H-2 determinants are not lysed by immune thymus-derived lymphocytes but are lysed by other antiviral immune attack mechanisms.

Authors:  R M Zinkernagel; M B Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

4.  Leukocyte cytotoxicity in a persistent virus infection: presence of direct cytotoxicity but absence of antibody-dependent cellular cytotoxicity in horses infected with equine infectious anemia virus.

Authors:  Y Fujimiya; L E Perryman; T B Crawford
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

5.  Cell-mediated cytotoxicity against murine cells infected with 6/94 virus, a parainfluenza type 1 isolate from multiple sclerosis brain tissue.

Authors:  L J Lewandowski; W U Gerhard; J C Palmer
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

6.  Cell-mediated cytotoxicity to herpes-infected cells in humans: dependence on antibodies.

Authors:  A Moller-Larsen; I Heron; S Haahr
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

7.  Specific immune lysis of paramyxovirus-infected cells by H-2-compatible thymus-derived lymphocytes.

Authors:  P C Doherty; R M Zinkernagel
Journal:  Immunology       Date:  1976-07       Impact factor: 7.397

8.  Lymphocyte cytotoxicity to influenza virus-infected cells: response to vaccination and virus infection.

Authors:  S B Greenberg; B S Criswell; H R Six; R B Couch
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

9.  Natural cytotoxic cell activity linked to time of recurrence of herpes labialis.

Authors:  M Rola-Pleszczynski; H Lieu
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.